4.9000
-0.3100
(-5.95%)
At close: January 10 at 4:00:00 PM EST
5.1200
+0.22
+(4.49%)
After hours: January 10 at 6:58:53 PM EST
Insider Purchases Last 6 Months
| Shares | Transactions | |
|---|---|---|
| Purchases | 0 | 0 |
| Sales | -- | 0 |
| Net Shares Purchased (Sold) | 0 | 0 |
| Total Insider Shares Held | 7.61M | -- |
| % Net Shares Purchased (Sold) | -- | -- |
Net Institutional Purchases Prior Quarter to Latest Quarter
| Shares | |
|---|---|
| Net Shares Purchased (Sold) | -- |
| % Change in Institutional Shares Held | -- |
Insider Transactions Reported - Last Two Years
| Insider | Transaction | Type | Value | Date |
|---|---|---|---|---|
| EVANS DARON Chief Financial Officer | Purchase at price 4.29 per share. | Direct | 42,900 | Dec 18, 2024 |
| EVANS DARON Chief Financial Officer | Purchase at price 4.60 per share. | Direct | 41,400 | Dec 12, 2024 |
| EVANS DARON Chief Financial Officer | Purchase at price 5.04 per share. | Direct | 53,167 | Dec 9, 2024 |
| HOGENHUIS WLADIMIR Director | Purchase at price 4.70 per share. | Direct | 20,017 | Sep 24, 2024 |
| HOGENHUIS WLADIMIR Director | Purchase at price 4.15 per share. | Direct | 19,982 | Jun 25, 2024 |
| EVANS DARON Chief Financial Officer | Purchase at price 4.04 per share. | Indirect | 161,568 | Jun 14, 2024 |
| ROBERTS BRIAN KENNETH Officer | Purchase at price 3.91 - 3.97 per share. | Indirect | 29,743 | Jun 14, 2024 |
| EVANS DARON Chief Financial Officer | Purchase at price 3.50 per share. | Direct | 1,578 | May 29, 2024 |
| EVANS DARON Chief Financial Officer | Purchase at price 2.85 - 3.23 per share. | Indirect | 9,668 | May 24, 2024 |
| ROBERTS BRIAN KENNETH Officer | Purchase at price 2.68 - 2.72 per share. | Direct | 20,138 | May 23, 2024 |
| ROBERTS BRIAN KENNETH Officer | Purchase at price 2.55 per share. | Indirect | 1,275 | Mar 28, 2024 |
| EVANS DARON Chief Financial Officer | Purchase at price 1.69 per share. | Indirect | 33,830 | Mar 15, 2024 |
| ROBERTS BRIAN KENNETH Officer | Purchase at price 1.88 per share. | Indirect | 18,800 | Mar 14, 2024 |
| EVANS DARON Chief Financial Officer | Purchase at price 1.93 per share. | Direct | 96,345 | Mar 8, 2024 |
| KIM YOUNG-JIN Director | Purchase at price 1.91 - 3.08 per share. | Direct | 313,016 | Mar 7, 2024 |
| ROBERTS BRIAN KENNETH Officer | Purchase at price 1.85 per share. | Indirect | 925 | Mar 7, 2024 |
| ROBERTS BRIAN KENNETH Officer | Purchase at price 1.85 per share. | Indirect | 925 | Mar 7, 2024 |
| ELAM NEVAN C Chief Executive Officer | Purchase at price 1.68 per share. | Direct | 8,400 | Feb 26, 2024 |
| ROBERTS BRIAN KENNETH Officer | Purchase at price 1.69 - 1.70 per share. | Direct | 13,540 | Feb 26, 2024 |
| EVANS DARON Chief Financial Officer | Purchase at price 1.30 - 1.37 per share. | Indirect | 66,741 | Feb 16, 2024 |
| ROBERTS BRIAN KENNETH Officer | Purchase at price 1.31 per share. | Direct | 9,142 | Feb 16, 2024 |
| ROBERTS BRIAN KENNETH Officer | Purchase at price 1.90 per share. | Direct | 9,500 | Jul 3, 2023 |
Related Tickers
STOK Stoke Therapeutics, Inc.
9.00
+0.45%
CMMB Chemomab Therapeutics Ltd.
2.1200
-4.50%
VYNE VYNE Therapeutics Inc.
3.4300
-12.50%
ZNTL Zentalis Pharmaceuticals, Inc.
2.7500
-1.08%
LRMR Larimar Therapeutics, Inc.
3.6600
-3.43%
CLYM Climb Bio, Inc.
2.0000
+6.95%
ATYR aTyr Pharma, Inc.
3.5300
-5.61%
ANNX Annexon, Inc.
4.8300
-0.21%
INZY Inozyme Pharma, Inc.
1.9950
-28.75%
SLRN Acelyrin, Inc.
2.0600
-3.74%